Clinical Trial Update: Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting safety and efficacy results for 72-hour and 120-hour infusions of rigosertib in acute myeloid leukemia and acute lymphoblastic l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED